Back to Directory

Peginterferon Alfa

Performance & Endurance

PEGylated interferon for hepatitis C and B, immune system modulator.

Key Benefits

  • ✓Treats hepatitis C and B
  • ✓Immune system activation
  • ✓Antiviral effects
  • ✓Weekly dosing vs 3x/week
  • ✓Anticancer effects

Dosing Information

Dosage Range
180 mcg
Frequency
Once weekly
Typical Duration
24-48 weeks for HCV

Detailed Protocol

Administered via subcutaneous injection once weekly. Multiple formulations (alfa-2a, alfa-2b). Dose may require adjustment based on side effects. Prescription only.

About Peginterferon Alfa

Peginterferon alfa is interferon alfa conjugated to polyethylene glycol (PEG) for extended half-life, allowing once-weekly dosing. FDA-approved for chronic hepatitis C (often with antivirals) and hepatitis B. Strong immune system effects.

Research Notes

FDA-approved for chronic hepatitis. Revolutionized HCV treatment before DAAs. Still used for HBV. Significant side effect profile requires monitoring. Less used now for HCV with DAAs available.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Flu-like symptoms (very common)
  • •Fatigue
  • •Depression
  • •Cytopenias
  • •Thyroid dysfunction
  • •Requires monitoring

Always consult with a healthcare professional before starting any peptide therapy.